Phase 2 motor study of Omaveloxolone in patients with mitochondrial myopathies

Prof. John Vissing from Copenhagen University, Copenhagen, Denmark will participate to the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018 and talk about "Phase 2 motor study of Omaveloxolone in patients with mitochondrial myopathies".

According to the Prof. Vissing:

"Nrf2 is the key endogenous regulator of cellular antioxidant response. Omaveloxone activates Nrf2 and the antioxidant response. In a placebo-controlled, double-blind, dose-escalating trial, sponsored by Reata Pharmaceutical, we explored the effect and safety of this drug in 54 patients with genetically confirmed mitochondrial myopathy. Results from the trial will be discussed"

For more information about Targeting Mitochondria 2018, www.targeting-mitochondria.com